N/A N=67 Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV
Sleep Bruxism · Tooth Wear
Primary: Total Number of Nights of Splint Wear for Four Months Per Subject. — 93.6; 98.7 nights — p=0.23
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=23 Study of the Safety and Efficacy of Botox in Bruxism
Bruxism
Primary: Bruxism Questionnaire Baseline and at Week 4 — 19.4; 16.1; 24.0; 24.0 units on a scale — p=0.0394
N/A N=72 Comparison of Dry Needling and Two Botulinum Toxins for Bruxism
Bruxism · Sleep Bruxism, Adult · Awake Bruxism
Primary: Pain Intensity Measured by Visual Analog Scale (VAS) — 8.909; 8.957; 9.167; 1.591 VAS score (0-10)
N/A N=40 Sleep Apnoea Breathing Record Exploratory Study (SABRES)
Sleep Apnea
Primary: Correlation Between the Trial Device and an Established Device — 0.955 correlation coefficient
N/A N=25 Anti-Snoring Appliances and Airway Manipulation in Patients Undergoing Anesthetic Sedation
Airway Obstruction · Snoring · Sedation Complication
Primary: Combined Total Number of Airway Interventions During an Anesthetic Sedation Case — 7; 5 Airway Interventions
Phase 2 N=21 Occlusal Adjustment as Treatment for Chronic Orofacial Pain
Temporomandibular Joint Disorders · Orofacial Pain
Primary: Visual Analogic Scale for Pain Intensity (0-10) — 6.52; 4.8; .81; 2.05 units on a scale
N/A N=20 Dental Appliance for Parkinson's Disease
Parkinson Disease
Primary: Changes in Gait Velocity — 1.10; 1.15 m/s
Phase 3 N=604 OTC Mouthpiece for Snoring
Snoring
Primary: Snoring Severity Scale — -4.1 units on a scale — p=< 0.0001
Phase 3 N=58 Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders
Temporomandibular Disorders
Primary: Pain Intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)) — 5.40; 5.53; 3.90; 3.89 units on a scale
N/A N=10 SleepFlexTM Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Number of Participants With Freedom From SleepFlex-related Serious Adverse Events — 10 Participants
N/A N=40 Effects of Myofunctional Therapy With an Application in Severe Apnea/Hypopnea Sleep Obstructive Syndrome (MTASSAOS)
Obstructive Sleep Apnea-hypopnea Syndrome
Primary: Apnea Hypopnea Index (AHI) — 44.77; 47.36; 20.88; 35 events per hour — p=<0.001
N/A N=62 Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality
Obstructive Sleep Apnea
Primary: Respiratory Event Index (REI) at T2 — 12.8; 21.1; 9.3; 13.1 number of events per hour — p=0.152
Phase 4 N=14 Sleep and Breathing in the General Population - Chemical Stimuli
Sleep-disordered Breathing
Primary: The Central Apnea-hypopnea Index — 14.1; 29.9 events per hour
N/A N=74 Sleep Disordered Breathing and Chronic Pain
Sleep Apnea Syndromes
Primary: Number of Sleep Related Events Per Hour — 38.8; 17.4; 4.5; 7.6 events/hour — p=<0.001
Phase 2 N=100 Mandibular Advancement vs Home Treatment for Primary Snoring
Snoring
Primary: Percent Responders of Clinical Global Impression of Improvement Scale - Partner — 91; 58 percent of snorer responders
N/A N=58 In Home Assessment of Three Anti-Snoring Devices, a Cross Over Study
Snoring
Primary: Bed Partners' Rating of Sleep Disturbance Due to Partner Snoring — 5.0; 3.8; 4.4 units on a scale — p=<.001
N/A N=36 Continuous Transcutaneous Electrical Stimulation in Sleep Apnoea
Obstructive Sleep Apnoea
Primary: 4% Oxygen Desaturation Index (ODI, 4%) — 26.9; 19.5 oxygen desaturation events/hour
Phase 2 N=18 Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 39.1; 40.8 events/hour — p=>0.5
N/A N=18 Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea
Sleep Apnea · Sleep Disordered Breathing
Primary: Salivary Cortisol Level
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
N/A N=42 A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder
Obstructive Sleep Apnea
Primary: Residual Apnea Hypopnea Index — 3.9; 26.3 events per hour — p=<0.001
N/A N=26 Effect of Added Varnum Mouthpiece on Pharyngeal Collapsibility and Sleep Apnea Severity in Mouth Breathers.
Obstructive Sleep Apnea
Primary: Sleep Apnea Severity as Measured by Apnea-hypopnea Index (AHI) — 16.4; 15.8 Events/hour
N/A N=144 Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness
Sleep Apnea, Obstructive
Primary: Subjective Sleepiness — 11.8; 10.2; 9.9 units on a scale
Phase 3 N=72 Two Contrasting Interventions for Sleep Management
Primary Insomnia · Secondary Insomnia
Primary: Change in Subjective Measures of Sleep Using Medical Outcomes Study -Sleep Scale, From Baseline at 1-week Follow-up — 15.8; 16.1 units on a scale — p=0.84
N/A N=45 Understanding the Sleep Apnea/Insomnia Interaction
Sleep Apnea Syndromes · Sleep Initiation and Maintenance Disorders
Primary: Insomnia Severity Index Score — -8.2; -7.33; -6.27 score on a scale — p=0.8
N/A N=100 Mechanisms of Sleep Disruption Hyperalgesia
Sleep Deprivation · Pain
Primary: Spinal Sensitization as Assessed by Area of Secondary Hyperalgesia (2HA) After Two Nights of Uninterrupted Sleep and Two Nights of 8 Forced Awakenings — 1276.25…
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
N/A N=25 Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Objective Sleep Parameters
Phase 2 N=17 Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
Sleep Apnea, Obstructive
Primary: Genioglossus Activity During Non-rapid Eye Movement (NREM) Sleep Measured as Percent of Wakefulness Activity — 96; 75; 84; 93 percent wakefulness — p=0.01
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001